Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Demegen

1992 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
4 FINANCING ROUNDS
1 INVESTMENTS
Description

Developer of peptides for the treatment and prevention of infections caused due to multi drug resistant bacteria and fungi. The company develops products for the treatment of dermatological, vaginal, respiratory, ophthalmic and oral diseases with the peptides bind to and kill harmful microorganisms.

Website
Formerly Known As
Demeter BioTechnologies
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Par Advance Technologies
Primary Office
  • 100 Technology Drive
  • Suite 440B
  • Pittsburgh, PA 15219
  • United States

Demegen Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Demegen‘s full profile, request access.

Request full access to PitchBook

Demegen Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000000 01-Jan-2001 000000000000000000 Other Pharmaceuticals and Biotechnology
To view this company’s complete investment and acquisition history, request access »

Demegen Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Demegen‘s full profile, request access.

Request full access to PitchBook

Demegen Executive Team (1)

Name Title Board
Seat
Contact
Info
Richard Ekstrom Chief Executive Officer